ClinicalTrials.Veeva

Menu

Analysis of SARS-CoV2 Urine Viral Particles and Association With Proximal Tubular Dysfunction (CovUrinePTD)

C

Central Hospital, Nancy, France

Status

Unknown

Conditions

SARS-CoV2 Infection
Proximal Tubule Dysfunction

Treatments

Other: RT-PCR SARS-COV2 in urine

Study type

Observational

Funder types

Other

Identifiers

NCT04937712
2021-A00724-37

Details and patient eligibility

About

The primary goal is to detect Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) urine viral particles in patients in intensive care units, hospitalized for coronavirus Coronavirus Disease-19 (COVID-19) infection, and correlate the presence of the virus in the urine with proximal tubular dysfunction (defined by the association of at least 2 abnormalities: tubular proteinuria, renal phosphate leak, uricosuria, normoglycemic glycosuria, amino aciduria)

Enrollment

34 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Person and / or trustworthy person who has received complete information on the organization of the research and who has not opposed their participation and the use of their data
  • Hospitalized for ≥ 48 hours and ≤ 10 days
  • SARS-CoV-2 positive nasopharyngeal sample
  • Severity criteria: Lung involvement described as compatible with SARS-CoV-2 on radiography or scanner and partial pressure of oxygne (PaO2) / Fraction of inspired oxygen (FiO2) ≤ 300 mmHg and / or respiratory rate (RR) ≥ 30 / min

Exclusion criteria

  • Known chronic kidney disease, or initial Glomerular Filtration Rate (GFR) <60 ml / min / 1.73m2 or Renal Transplant
  • Known proteinuria
  • Known proximal tubulopathy
  • Treatment with Forxiga

Trial contacts and locations

1

Loading...

Central trial contact

Raphaël Kormann

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems